Smad4 May Help to Identify a Subset of Colorectal Cancer Patients with Early Recurrence after Curative Therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn, Byung Kyu | - |
dc.contributor.author | Jang, Si-Hyong | - |
dc.contributor.author | Paik, Seung Sam | - |
dc.contributor.author | Lee, Kang Hong | - |
dc.date.accessioned | 2022-07-16T18:24:25Z | - |
dc.date.available | 2022-07-16T18:24:25Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2011-11 | - |
dc.identifier.issn | 0172-6390 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/167253 | - |
dc.description.abstract | Background/Aims: Loss of Smad4 function is associated with the acquisition of advanced colorectal cancer phenotypes. We investigated the role of Smad4 as a prognostic marker after curative therapy. Methodology: Four hundred and twenty nine consecutive colorectal cancers were analyzed by tissue microarray-based immunohistochemical assay. Results: Smad4 protein was expressed in 61.5% (24/39), 53.1% (77/145), 41.3% (78/189) and 34.8% (16/46) of stage I, II, III and IV cancers, respectively. Lymphovascular invasion and lymph node metastasis were strongly correlated with the loss of Smad4 expression (p<0.0001 and p=0.002, respectively). Disease-free survival did not differ between Smad4-positive and Smad4-negative cancers. In stage Ill disease, time to recurrence after curative therapy was shorter in the Smad4-negative than in the Smad4-positive cancers (20.1 +/- 15.1 vs. 34.6 +/- 34.1 months, p=0.035). Conclusions: Smad4 protein is of no value in predicting recurrence after curative therapy in colorectal cancer, but it may be helpful in identifying a subset of patients with early recurrence after curative therapy. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | H G E UPDATE MEDICAL PUBLISHING S A | - |
dc.title | Smad4 May Help to Identify a Subset of Colorectal Cancer Patients with Early Recurrence after Curative Therapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Ahn, Byung Kyu | - |
dc.contributor.affiliatedAuthor | Paik, Seung Sam | - |
dc.contributor.affiliatedAuthor | Lee, Kang Hong | - |
dc.identifier.doi | 10.5754/hge11186 | - |
dc.identifier.scopusid | 2-s2.0-84863251477 | - |
dc.identifier.wosid | 000300532700018 | - |
dc.identifier.bibliographicCitation | HEPATO-GASTROENTEROLOGY, v.58, no.112, pp.1933 - 1936 | - |
dc.relation.isPartOf | HEPATO-GASTROENTEROLOGY | - |
dc.citation.title | HEPATO-GASTROENTEROLOGY | - |
dc.citation.volume | 58 | - |
dc.citation.number | 112 | - |
dc.citation.startPage | 1933 | - |
dc.citation.endPage | 1936 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalResearchArea | Surgery | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Surgery | - |
dc.subject.keywordPlus | 18Q ALLELIC LOSS | - |
dc.subject.keywordPlus | CHROMOSOME 18Q | - |
dc.subject.keywordPlus | COLON-CANCER | - |
dc.subject.keywordPlus | GENE | - |
dc.subject.keywordPlus | PROGNOSIS | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordAuthor | Smad4 | - |
dc.subject.keywordAuthor | Colorectal cancer | - |
dc.subject.keywordAuthor | Carcinogenesis | - |
dc.subject.keywordAuthor | Prognosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.